TNF and rheumatoid arthritis: In another study, TCZ treatment resulted in fewer cardiovascular events than TNF-α inhibitors (hazard ratios, HR 0.68; 95% confidence interval, CI 0.49 to 0.94) among RA patients who switched from a different biologic drug or tofacitinib to TCZ versus a TNF-α [47].